| Trump’s AI masterplan:
While the media is busy ranting and raving about Donald Trump’s new AI plans, or the $5o0 billion project OpenAI is funding… there’s one story that no news station is covering. Yet it could be the most important financial story in the world. Exposed in this new documentary is the incredible story of the next great technology advancement – a paradigm shifting breakthrough that could potentially make early investors wildly wealthy.
I’m not talking about AI… Quantum computing… augmented reality… the blockchain… or anything else you might be thinking of. No. This is far bigger than them all. It’s the cornerstone that many of our recent technological innovations have been built upon… and the future will be built upon too. For those on the frontier? Fortunes could be made. Which is why investors like Marc Andreessen, Ben Horowitz, Elon Musk, Jeff Bezos, Mark Zuckerberg, Jensen Huang, Bill Gates, and many others are pouring billions into it. Be warned though: There is a dark side to this story too. You see, while the future of this new technology is written in stone… the road ahead is bumpy and paved with hazards. And in a mirror of every big tech revolution… whether it was the railroads in the 1800s or the dot-com boom in the late 90s… while investing in the underlying trend was the right thing to do… If you owned the wrong companies – or bought the right companies at the wrong time – you would have been wiped out. That’s why it’s critical that you watch this documentary to fully understand what’s really going on… and how to best capitalize on the trillion-dollar revolution it will usher in. |
Just weeks ago, we said one of the most oversold pharmaceutical stocks to buy for the long haul was AbbVie (SYM: ABBV).
In fact, on January 14, the pharmaceutical giant was trading at about $172. Today, it’s up to S192.72 and could easily refill its bearish gap at around $200 a share. Plus, if you were a shareholder as of January 15, you’ll get the company’s $1.64 dividend this month.
Helping, AbbVie said it generated $15.1 billion in sales and an adjusted profit of $2.16 a share. Sales, up 5.6% year over beat, beat forecasts for $14.83 billion.
And while earnings sank 23%, they still topped expectations for $2.12.
“Importantly, AbbVie’s immunological powerhouses, Skyrizi and Rinvoq, generated a respective $3.78 billion and $1.83 billion in sales. Skyrizi revenue rocketed nearly 58% vs. the year-earlier period, while Rinvoq sales jumped more than 46%. Both beat expectations and helped offset a sales miss for Humira,” added Investor’s Business Daily.
Guidance wasn’t too shabby either.
For full-year 2025. The company expects to post EPS of between $12.12 and $12.32, as compared to estimates of $12.13.
Plus, according to ABBV CEO Robert Michael:
“2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data, and we strengthened our business through strategic transactions. We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.”
In short, ABBV offers significant upside potential moving forward.
Congratulations to those of you that did pick up ABBV shares. Not only are you up about $20 a share, but you’ll also receive the company’s $1.64 dividend.
